Drug Profile
VIC 1911
Alternative Names: TAS-119; TAS-2104; VIC-1911Latest Information Update: 30 Jan 2024
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical
- Developer Taiho Pharmaceutical; VITRAC Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Aurora kinase A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Graft-versus-host disease
- Phase I Non-small cell lung cancer
- Preclinical Triple negative breast cancer
- Discontinued Solid tumours
Most Recent Events
- 09 Dec 2023 Pharmacodynamic and safety data from phase I/II trial in Graft vs host disease presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 11 Oct 2023 Preclinical trials in Triple-negative-breast-cancer (PO) prior to October 2023
- 11 Oct 2023 Pharmacodynamics data from preclinical studies in Triple-negative breast cancer presented at the International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)